Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 198

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target

Zhao, Shuang G, Lehrer, Jonathan, Chang, S Laura, Das, Rajdeep, Erho, Nicholas, Liu, Yang, Sjöström, Martin, Den, Robert B, Freedland, Stephen J, Klein, Eric A, Karnes, R Jeffrey, Schaeffer, Edward M, Xu, Melody, Speers, Corey, Nguyen, Paul L, Ross, Ashley E, Chan, June M, Cooperberg, Matthew R, Carroll, Peter R, Davicioni, Elai, Fong, Lawrence, Spratt, Daniel E, Feng, Felix Y · 2019 · JNCI: Journal of the National Cancer Institute

Abstract

BACKGROUND: Immunotherapy has been less successful in treating prostate cancer than other solid tumors. We sought to better understand the immune landscape in prostate cancer and identify immune-related biomarkers and potential therapeutic targets. METHODS: We analyzed gene expression data from 7826 prospectively collected prostatectomy samples (2013-2016), and 1567 retrospective samples with long-term clinical outcomes, for a total of 9393 samples, all profiled on the same commercial clinical platform in a CLIA-certified lab. The primary outcome was distant metastasis-free survival (DMFS). Secondary outcomes included biochemical recurrence-free survival (bRFS), prostate cancer-specific survival (PCSS), and overall survival (OS). All statistical tests were two-sided. RESULTS: Unsupervised hierarchical clustering of hallmark pathways demonstrated an immune-related tumor cluster. Increased estimated immune content scores based on immune-specific genes from the literature were associated with worse bRFS (hazard ratio [HR] = 1.26 [95% confidence interval [CI] = 1.12 to 1.42]; P < .001), DMFS (HR = 1.34 [95% CI = 1.13 to 1.58]; P < .001), PCSS (HR = 1.53 [95% CI = 1.21 to 1.92]; P < .001), and OS (HR = 1.27 [95% CI = 1.07 to 1.50]; P = .006). Deconvolution using Cibersort revealed that mast cells, natural killer cells, and dendritic cells conferred improved DMFS, whereas macrophages and T-cells conferred worse DMFS. Interestingly, while PD-L1 was not prognostic, consistent with its low expression in prostate cancer, PD-L2 was expressed at statistically significantly higher levels (P < .001) and was associated with worse bRFS (HR = 1.17 [95% CI = 1.03 to 1.33]; P = .01), DMFS (HR = 1.25 [95% CI = 1.05 to 1.49]; P = .01), and PCSS (HR = 1.45 [95% CI = 1.13 to 1.86]; P = .003). PD-L2 was strongly associated with immune-related pathways on gene set enrichment analysis suggesting that it is playing an important role in immune modulation in clinical prostate cancer samples. Furthermore, PD-L2 was correlated with radiation response pathways, and also predicted response to postoperative radiation therapy (PORT) on multivariable interaction analysis (P = .03). CONCLUSION: In the largest study of its kind to date, these results illustrate the complex relationship between the tumor-immune interaction, prognosis, and response to radiotherapy, and nominate PD-L2 as a potential novel therapeutic target in prostate cancer, potentially in combination with radiotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djy141

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 198

Metadata

Authors
Zhao, S. G., Lehrer, J., Chang, S. L., Das, R., Erho, N., Liu, Y., Sjöström, M., Den, R. B., Freedland, S. J., Klein, E. A., Karnes, R. J., Schaeffer, E. M., Xu, M., Speers, C., Nguyen, P. L., Ross, A. E., Chan, J. M., Cooperberg, M. R., Carroll, P. R., Davicioni, E., Fong, L., Spratt, D. E., & Feng, F. Y.
Venue
JNCI: Journal of the National Cancer Institute
Published
2018-10-13
Volume
111
Issue
3
Pages
301-310
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2896846797
Cited by
198
References
8
FWCI
7.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. https://app.cochat.ai/papers/10.1093/jnci/djy141
The paper
Zhao, S. G., Lehrer, J., Chang, S. L., Das, R., Erho, N., Liu, Y., Sjöström, M., Den, R. B., Freedland, S. J., Klein, E. A., Karnes, R. J., Schaeffer, E. M., Xu, M., Speers, C., Nguyen, P. L., Ross, A. E., Chan, J. M., Cooperberg, M. R., Carroll, P. R., . . . Feng, F. Y. (2019). The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djy141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.